Welcome to our dedicated page for Incyte Genomics news (Ticker: INCY), a resource for investors and traders seeking the latest updates and insights on Incyte Genomics stock.
Incyte Genomics Inc. (Symbol: INCY) is a leading biopharmaceutical company dedicated to the discovery, development, and commercialization of proprietary therapeutics, with a primary focus on oncology. Headquartered in Wilmington, Delaware, Incyte employs over 625 professionals across its management, discovery, clinical development, and commercial teams.
The company’s flagship product, Jakafi, is a groundbreaking treatment for rare blood cancers and graft versus host disease, developed in partnership with Novartis. Incyte has also made significant strides with its other marketed drugs, including Olumiant for rheumatoid arthritis (licensed to Eli Lilly), Iclusig for chronic myeloid leukemia, Pemazyre for cholangiocarcinoma, Tabrecta for lung cancer, and Monjuvi for diffuse large B-cell lymphoma. Additionally, Incyte's first dermatology product, Opzelura, received approval in 2021 for atopic dermatitis and in 2022 for vitiligo.
Incyte’s pipeline includes a wide array of innovative oncology and dermatology programs, demonstrating their commitment to addressing serious unmet medical needs. The company's strategic collaborations with major pharmaceutical firms further support the clinical development and global commercialization of its compounds.
Incyte’s financial health and robust portfolio position it strongly to continue improving patient lives while building sustainable value for its shareholders. For the latest updates on Incyte’s projects and developments, visit their corporate website at www.incyte.com.
Incyte announced a $2.0 billion share repurchase authorization, with a Dutch Auction tender offer to repurchase up to $1.672 billion of outstanding common shares. The offer reflects confidence in the company's future outlook, product portfolio, and clinical pipeline. A separate stock purchase agreement with Baker Entities will repurchase up to $328.0 million of common stock, enabling them to maintain their ownership level. The tender offer, expiring on June 10, 2024, allows stockholders to tender shares within a price range for repurchase.
Incyte (Nasdaq:INCY) will be presenting at the Bank of America Securities 2024 Health Care Conference on May 15, 2024, in Las Vegas. The presentation will be webcast live and available for replay for 30 days.
Incyte reports total revenues of $881 million in Q1'24, up 9% Y/Y, with Jakafi® net product revenues at $572 million, Opzelura® at $86 million, and plans to acquire Escient Pharmaceuticals. The company made progress with clinical pipeline and key agreements for drug development.
FAQ
What is the current stock price of Incyte Genomics (INCY)?
What is the market cap of Incyte Genomics (INCY)?
What is Incyte Genomics Inc. known for?
Where is Incyte Genomics Inc. headquartered?
What is Jakafi?
Which drugs has Incyte marketed?
What is Opzelura used for?
Does Incyte collaborate with other pharmaceutical companies?
How many employees work at Incyte?
What is Incyte's vision?
How can I get more information about Incyte?
What areas does Incyte's pipeline cover?
